At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people
with cancer live longer and better than ever before. We are a commercial stage oncology innovator
seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and
chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and
dedicated to serving the patient community by delivering therapeutics that provide meaningful and
differentiated clinical results and address urgent unmet need.
